- Home
- CUB vs PGEN Comparison
CUB vs PGEN Comparison
Compare CUB & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUB
- PGEN
- Stock Information
- Founded
- CUB 2024
- PGEN 1998
- Country
- CUB United States
- PGEN United States
- Employees
- CUB N/A
- PGEN N/A
- Industry
- CUB
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CUB
- PGEN Health Care
- Exchange
- CUB NYSE
- PGEN Nasdaq
- Market Cap
- CUB 322.0M
- PGEN 475.2M
- IPO Year
- CUB 2024
- PGEN N/A
- Fundamental
- Price
- CUB $10.49
- PGEN $1.85
- Analyst Decision
- CUB
- PGEN Strong Buy
- Analyst Count
- CUB 0
- PGEN 3
- Target Price
- CUB N/A
- PGEN $6.00
- AVG Volume (30 Days)
- CUB 48.5K
- PGEN 2.2M
- Earning Date
- CUB 08-22-2025
- PGEN 08-13-2025
- Dividend Yield
- CUB N/A
- PGEN N/A
- EPS Growth
- CUB N/A
- PGEN N/A
- EPS
- CUB 0.34
- PGEN N/A
- Revenue
- CUB N/A
- PGEN $4,201,000.00
- Revenue This Year
- CUB N/A
- PGEN $256.94
- Revenue Next Year
- CUB N/A
- PGEN $759.81
- P/E Ratio
- CUB $31.24
- PGEN N/A
- Revenue Growth
- CUB N/A
- PGEN N/A
- 52 Week Low
- CUB $9.96
- PGEN $0.65
- 52 Week High
- CUB $10.61
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- CUB N/A
- PGEN 68.77
- Support Level
- CUB N/A
- PGEN $1.56
- Resistance Level
- CUB N/A
- PGEN $2.04
- Average True Range (ATR)
- CUB 0.00
- PGEN 0.11
- MACD
- CUB 0.00
- PGEN 0.04
- Stochastic Oscillator
- CUB 0.00
- PGEN 70.00
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.